Welcome to our dedicated page for 908 Devices SEC filings (Ticker: MASS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC filings from 908 Devices Inc. often read like a second doctoral thesis—dense tables on high-pressure mass spectrometry R&D, intricate revenue splits for handheld versus desktop analyzers, and pages of export-control fine print. If you’ve wondered “how do I find a 908 Devices quarterly earnings report 10-Q filing” or “where are 908 Devices insider trading Form 4 transactions?”, you’re not alone.
Stock Titan solves that problem. Our AI scans every 10-K, 10-Q, 8-K and proxy the moment it hits EDGAR, then delivers clear, plain-English highlights. Need the story behind a sudden 8-K product recall? Curious about 908 Devices executive stock transactions Form 4? The platform flags them in real time, summarizes key numbers, and links you straight to the source—no manual searching, no jargon overload.
Use this page to:
- Review the 908 Devices annual report 10-K simplified and see R&D spend next to device revenue
- Run a 908 Devices earnings report filing analysis to compare margins quarter over quarter
- Set alerts for 908 Devices Form 4 insider transactions real-time before market moves
- Find the 908 Devices proxy statement executive compensation without wading through footnotes
- Have 908 Devices 8-K material events explained by AI within minutes
Whether you’re a life-sciences analyst assessing supply-chain risk or a trader tracking insider sentiment, understanding 908 Devices SEC documents with AI turns hours of reading into focused insight. It’s the fastest way to get 908 Devices SEC filings explained simply, without missing a critical detail.
Christopher D. Brown filed an initial Statement of Beneficial Ownership (Form 3) for 908 Devices (MASS) following his appointment as Director. The filing reveals significant equity holdings as of June 13, 2025:
- Direct Common Stock ownership: 962,122 shares
- Stock Options: Total of 320,404 shares at various exercise prices ranging from $1.75 to $16.66, with different vesting schedules
- Restricted Stock Units (RSUs): 52,837 units vesting over four annual installments from 2022-2024
The stock options include both fully vested options and those with future vesting schedules through 2025. RSUs represent contingent rights to receive common stock upon vesting, with no expiration date. This substantial equity position aligns the director's interests with shareholders and indicates a long-term commitment to the company.
Michael S. Turner, Chief Legal & Administrative Officer of 908 Devices (MASS), executed a series of planned stock sales under a Rule 10b5-1 trading plan over three consecutive days in June 2025:
- June 16: Sold 16,082 shares at weighted average price of $7.5139
- June 17: Sold 7,148 shares at weighted average price of $7.506
- June 18: Sold remaining 1,373 shares at $7.50
The transactions resulted in a complete liquidation of Turner's direct common stock holdings, reducing his position from 24,603 shares to zero. All sales were executed pursuant to a pre-established Rule 10b5-1 trading plan, which provides a safe harbor from insider trading allegations by determining the timing and terms of trades in advance.
FAQ
What is the current stock price of 908 Devices (MASS)?
What is the market cap of 908 Devices (MASS)?
What is the primary focus of 908 Devices Inc.?
How do 908 Devices Inc.'s products differentiate from traditional chemical analysis tools?
Which industries benefit most from the company’s technology?
What is the significance of high pressure mass spectrometry in their solutions?
How does the company maintain versatility in its product offerings?
What geographical markets does 908 Devices Inc. serve?
How does 908 Devices Inc. ensure its products are user-centric?
What makes 908 Devices Inc.'s approach unique in chemical analysis?
